PDF(Pubmed)
Abstract：
Due to its overexpression on the surface of prostate cancer cells, prostate-specific membrane antigen (PSMA) is a relatively novel effective target for molecular imaging and radioligand therapy (RLT) in prostate cancer. Recent studies reported that PSMA is expressed in the neovasculature of various types of cancer and regulates tumour cell invasion as well as tumour angiogenesis. Several authors explored the role of diagnostic and therapeutic PSMA radioligands in various malignancies. In this narrative review, we describe the current status of the literature on PSMA radioligands\' application in solid tumours other than prostate cancer to explore their potential role as diagnostic or therapeutic agents, with particular regard to the relevance of PSMA radioligand uptake as neoangiogenetic biomarker. Hence, a comprehensive review of the literature was performed to find relevant articles on the applications of PSMA radioligands in non-prostate solid tumours. Data on the general, methodological and clinical aspects of all included studies were collected. Forty full-text papers were selected for final review, 8 of which explored PSMA radioligand PET/CT performances in gliomas, 3 in salivary gland malignancies, 6 in thyroid cancer, 2 in breast cancer, 16 in renal cell carcinoma and 5 in hepatocellular carcinoma. In the included studies, PSMA radioligand PET showed promising performance in patients with non-prostate solid tumours. Further studies are needed to better define its potential role in oncological patients management, especially in those undergoing antineoangiogenic therapies, and to assess the efficacy of PSMA-RLT in this clinical context.
摘要：
由于其在前列腺癌细胞表面的过度表达，前列腺特异性膜抗原（PSMA）是前列腺癌分子成像和放射性配体治疗（RLT）的一个相对新颖的有效靶点。最近的研究报道PSMA在各种类型的癌症的新血管中表达,并且调节肿瘤细胞侵袭以及肿瘤血管生成。几位作者探讨了诊断和治疗PSMA放射性配体在各种恶性肿瘤中的作用。在这篇叙述性评论中，我们描述了PSMA放射性配体在前列腺癌以外的实体瘤中应用的文献现状，以探讨其作为诊断或治疗药物的潜在作用。特别是关于PSMA放射性配体摄取作为新血管生成生物标志物的相关性。因此，我们对文献进行了全面回顾,以找到有关PSMA放射性配体在非前列腺实体瘤中应用的相关文章.一般数据，收集所有纳入研究的方法学和临床方面.全文共选择了四十篇论文进行终审,其中8个探讨了PSMA放射性配体PET/CT在胶质瘤中的表现，3在唾液腺恶性肿瘤中，6在甲状腺癌中，2在乳腺癌中，肾细胞癌中16例，肝细胞癌中5例。在纳入的研究中，PSMA放射性配体PET在非前列腺实体瘤患者中显示出良好的性能。需要进一步的研究来更好地定义其在肿瘤患者管理中的潜在作用，尤其是那些正在接受抗肿瘤血管生成治疗的患者，并评估PSMA-RLT在这种临床背景下的疗效。
